What are the differences in efficacy and side effects between a conventional 20‑fraction external beam radiotherapy regimen and a 5‑fraction stereotactic body radiotherapy (SBRT) regimen for early‑stage prostate cancer?

5-Fraction SBRT Demonstrates Non-Inferior Efficacy with Comparable Safety to 20-Fraction Radiotherapy for Early Prostate Cancer

For patients with low-to-intermediate risk early prostate cancer, 5-fraction SBRT (36.25 Gy) is non-inferior to conventional or moderately hypofractionated radiotherapy (20-39 fractions) in terms of biochemical control, with similar or lower rates of late toxicity, making it a preferred option given the substantial reduction in treatment time from 4-8 weeks to 1-2 weeks. 1

Efficacy Outcomes

The most definitive evidence comes from the 2024 PACE-B phase 3 trial 1, which directly compared 5-fraction SBRT (36.25 Gy) versus control radiotherapy (78 Gy/39 fractions or 62 Gy/20 fractions) in 874 patients with low-to-intermediate risk prostate cancer:

• 5-year biochemical/clinical failure-free survival: 95.8% (SBRT) vs 94.6% (control), demonstrating non-inferiority (HR 0.73, p=0.004 for non-inferiority)
• Median follow-up: 74 months—providing robust long-term data
• Both regimens achieved excellent disease control rates exceeding 94%

Real-world data from Canadian centers 2 corroborates these findings with 5-year biochemical relapse-free survival of 92.1% for SBRT versus 93.6% for hypofractionated RT, with no significant differences in overall survival (96.4% vs 95.0%).

Key efficacy advantage: SBRT achieved significantly lower PSA nadirs (0.18 ng/ml vs 0.48 ng/ml in low-risk patients), suggesting more complete tumor ablation 2.

Side Effect Profile

Acute Toxicity (During/Within 3 Months of Treatment)

The PACE-B trial 3 demonstrated that SBRT does not increase acute toxicity:

• Grade ≥2 GI toxicity: 10% (SBRT) vs 12% (conventional/moderate hypofractionation), p=0.38
• Grade ≥2 GU toxicity: 23% (SBRT) vs 27% (conventional/moderate hypofractionation), p=0.16
• No treatment-related deaths in either arm

This contradicts earlier concerns about ultra-hypofractionation increasing acute side effects.

Late Toxicity (2+ Years Post-Treatment)

At 24 months 4:

• Grade ≥2 GU toxicity: 3% (SBRT) vs 2% (control), p=0.39—essentially equivalent
• Grade ≥2 GI toxicity: 2% (SBRT) vs 3% (control), p=0.32—essentially equivalent
• No grade 4+ toxicities or treatment-related deaths

However, at 5 years, the PACE-B trial 1 showed a divergence:

• Grade ≥2 GU toxicity: 26.9% (SBRT) vs 18.3% (control), p<0.001—higher with SBRT
• Grade ≥2 GI toxicity: 10.7% (SBRT) vs 10.2% (control), p=0.94—equivalent

Critical caveat: The increased late GU toxicity with SBRT (8.6% absolute difference) represents the main trade-off for the dramatically shorter treatment course. This primarily manifests as urinary frequency, urgency, and nocturia rather than incontinence.

Real-world Chinese data 5 showed lower rates: 12.9% grade ≥2 GU toxicity and 16.1% grade ≥2 GI toxicity with SBRT versus 22.2% and 29.3% respectively with conventional RT, though differences were not statistically significant.

Quality of Life Impact

Patient-reported outcomes favor SBRT in the acute phase 3:

• Bowel QoL decline at 1 month: -1.9 (SBRT) vs -10.4 (conventional), p=0.0008
• Urinary domain decline: -7.5 (SBRT) vs -11.3 (conventional)
• IPSS worsening at 1 week: +4.55 (SBRT) vs +7.49 (conventional), p=0.062

The shorter treatment duration (1-2 weeks vs 4-8 weeks) provides substantial practical advantages: reduced time away from work, fewer transportation requirements, lower costs, and decreased COVID-19/infection exposure risk.

Guideline Recommendations

The 2019 ASTRO/ASCO/AUA guidelines 6 provide conditional recommendations for ultra-hypofractionated RT in low-to-intermediate risk disease, strongly encouraging treatment of intermediate-risk patients on clinical trials or registries. However, the 2024 PACE-B results 1 now provide the high-quality randomized evidence that was previously lacking.

The 2024 EAU guidelines 7 offer SBRT as a weak recommendation: "Offer ultrahypofractionated IMRT/IGRT or SBRT, using either 36.25 Gy (40 Gy to the prostate) in 5 fx or 42.7 Gy in 7 fx delivered on alternate days" for intermediate-risk disease.

The 2014 NCCN guidelines 8 noted SBRT as "emerging" with excellent biochemical control (95% for low-risk, 84% for intermediate-risk at 5 years) but cautioned that "longer follow-up and prospective multi-institutional data are required" due to theoretical concerns about late toxicity. The PACE-B trial has now provided this long-term prospective data.

Clinical Algorithm for Treatment Selection

Choose 5-fraction SBRT when:

• Low or favorable intermediate-risk disease (Gleason ≤3+4, PSA <20, ≤cT2a)
• Patient prioritizes treatment convenience and shorter duration
• Clinic has appropriate IGRT technology and expertise
• Patient accepts 8-6% higher risk of late grade ≥2 GU symptoms

Choose 20-fraction moderate hypofractionation when:

• Patient has baseline significant urinary symptoms (IPSS >15)
• History of prior TURP (higher baseline GU toxicity risk)
• Patient prioritizes minimizing late GU toxicity over treatment duration
• Unfavorable intermediate-risk features (multiple intermediate-risk factors)

Avoid SBRT in:

• High-risk disease requiring pelvic nodal irradiation (insufficient evidence, though emerging data 9 suggests feasibility)
• Prior pelvic radiation
• Active inflammatory bowel disease
• Very low bladder capacity

Common Pitfalls

1. Overestimating acute toxicity risk: SBRT does not increase acute side effects compared to longer regimens
2. Underestimating late GU toxicity: The 8.6% absolute increase in grade ≥2 late GU toxicity is real and should be discussed during informed consent
3. Inappropriate patient selection: SBRT requires precise IGRT—facilities without daily image guidance should not offer this approach
4. Ignoring baseline urinary function: Patients with pre-existing significant urinary symptoms may experience worse outcomes with SBRT

The radiobiologic rationale for SBRT's efficacy lies in prostate cancer's low α/β ratio (1-4), similar to or lower than surrounding normal tissues 8. This means larger fraction sizes are theoretically more effective against prostate cancer without proportionally increasing late toxicity—a prediction largely confirmed by the PACE-B trial, with the exception of late GU effects.